Dendritic cell therapy based on nepantigen-gene analysis
- Conditions
- Malignant tumor (except leukemia)
- Registration Number
- JPRN-jRCTc030210026
- Lead Sponsor
- Tanigawa Keishi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Patients must:
- have ECOG Performance Status for 0, 1 or 2.
- maintain adequate function of key organs when the eligibility is confirmed, in particular:
1. haemoglobin 8.0 g/dl or more
2. platelet 50.000 /mm3 or more
3. total bilirubin 3 x ULN or more
4. AST/ALT 3 x ULN or less
5. creatinine 3 x ULN or less
- provide written consent for treatment of neoantigens-loaded DC vaccination.
- have a proper mental condition and an ability to recognize the object and contents of the study when informed consent is obtained.
Patients must not:
- be impossible to obtain blood sample by Leukapeheresis.
- be positive in HIV antibody test.
- have active auto-immune disorder.
- have serious underlying disease.
- be pregnant (including pregnancy seeker)
- be judged ineligibles by clinician in this trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method